Group 1 - The recombinant protein concept sector rose by 2.32%, ranking fifth among concept sectors, with 40 stocks increasing in value [1] - Notable gainers in the sector included Xilong Science, which hit the daily limit, and other companies like Maiwei Biotech, Hotgen Biotech, and Zexin Pharmaceutical, which rose by 11.05%, 8.16%, and 7.91% respectively [1] - The sector experienced a net inflow of 354 million yuan from main funds, with 23 stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top stocks by net inflow included Xilong Science with 282 million yuan, followed by Huabei Pharmaceutical, Borui Pharmaceutical, and Maiwei Biotech with net inflows of 29.71 million yuan, 27.06 million yuan, and 14.97 million yuan respectively [2][3] - Xilong Science led the sector with a net inflow rate of 30.58%, followed by Innotec and Kexing Pharmaceutical with rates of 13.12% and 11.83% respectively [3] - The overall performance of the recombinant protein sector reflects strong investor interest and capital flow, indicating potential growth opportunities within this industry [2][3]

Summary of the Conference Call for Maiwei Biotech Company Overview - Maiwei Biotech is an innovative biopharmaceutical company focused on oncology and age-related diseases, with a comprehensive industry chain layout [3][4]. Key Developments in Innovative Drugs - Significant progress has been made in both innovative drugs and biosimilars. The company has developed several best-in-class products using its ADC platform, including next-generation ADC technologies [3]. - The third-generation long-acting white blood cell enhancer 8MW0,511 is expected to be approved for market launch in 2025, with a peak sales potential of 798 million yuan [3][7]. - The Nectin-4 ADC (2,821) is the fastest progressing ADC in China, currently in Phase III clinical trials for indications such as urothelial carcinoma, cervical cancer, and triple-negative breast cancer, with a mid-term analysis expected in 2026-2027 [3][5]. - The only marketed Trop-2 ADC, Trodelvy, is projected to exceed $1.5 billion in sales in 2024, showing over 50% year-on-year growth [3][5]. Unique Advantages of ADC Platform - Maiwei Biotech's ADC platform has unique advantages in target selection, linker design, and payload selection, aimed at improving efficacy and safety [4]. - The company focuses on high-expression target antigens and employs DAR-controlled conjugation technology to enhance ADC stability and reduce off-target effects [4]. Clinical Stage ADC Products - The company has three ADC products in clinical stages: Nectin-4 ADC (2,821), Trop-2 ADC, and B7-H3 ADC, with Nectin-4 ADC being the most advanced [5]. - The sales peak for Nectin-4 ADC in urothelial carcinoma is estimated to reach 2.298 billion yuan [5]. Emerging Innovative Projects - In addition to the highlighted products, Maiwei Biotech is developing other promising projects, including white blood cell enhancer 8MW0,511 and other innovative drugs that show strong potential [6]. Progress in White Blood Cell Enhancers - The long-acting white blood cell enhancer 8MW0,511 has been accepted for market approval and is expected to fill a market gap upon its launch [7]. Other Innovative Therapies - The company is advancing several important pipelines, including SST2 inhibitors in COPD, which are in Phase III clinical trials, and a new oral drug for osteoarthritis, RP901, which is a first-in-class product [8]. Breakthroughs in Pulmonary Fibrosis Treatment - Maiwei Biotech has developed a product, Batilizumab, for the treatment of idiopathic pulmonary fibrosis, which is expected to become a commercial development and licensing choice, accelerating its clinical development and commercialization [9]. Expectations in Biosimilars - The biosimilar business is gradually ramping up, with expected peak sales of 990 million yuan for Macon, 1.06 billion yuan for Meilisu, and 568 million yuan for Maiweijian [10]. Revenue Projections and Overall Assessment - Revenue projections for 2025 and 2026 are estimated at 850 million yuan and 1.514 billion yuan, respectively. The company is expected to focus on commercializing its differentiated targets globally and advancing its clinical pipeline [11].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [9]. Core Insights - The company is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout, focusing on ADCs, antibodies, and recombinant protein drugs, primarily targeting oncology and age-related diseases [5][17]. - The ADC technology platform is advanced, with the Nectin-4 ADC expected to become a best-in-class (BIC) product, showing promising clinical results compared to existing therapies [6][9]. - The company has a robust pipeline of innovative drugs and biosimilars, with significant revenue growth projected from 2024 to 2026 [8][10]. Summary by Sections Company Overview - The company was established in 2017 and went public on the Shanghai Stock Exchange in 2022, focusing on the research, production, and sales of biopharmaceuticals [17]. - It has 16 products at various stages, including 12 innovative products and 4 biosimilars, with 3 products already on the market [17]. ADC Technology Platform - The company has developed a next-generation ADC targeted conjugation technology platform (IDDCTM), which includes proprietary technologies that enhance drug stability and efficacy [6][28]. - The Nectin-4 ADC (9MW2821) is the fastest progressing ADC in China for treating urothelial carcinoma, currently in Phase III clinical trials [6][9]. Innovative Product Pipeline - The company is advancing multiple differentiated targets, including 9MW1911 (for COPD) and 9MW3011 (for blood disorders), with significant global development progress [7][30]. - The biosimilars have begun commercializing, contributing to cash flow for innovative drug development [7][30]. Financial Projections - Revenue forecasts for 2024, 2025, and 2026 are projected at 2.09 billion, 8.51 billion, and 15.14 billion RMB, respectively, with significant year-on-year growth rates [8][10]. - The company expects to achieve a net profit margin improvement, with net losses decreasing from 1.09 billion RMB in 2024 to 258 million RMB in 2026 [10].

Financial Performance - Total revenue for 2024 reached RMB 19,878.57 million, a 55.50% increase compared to RMB 12,783.55 million in the previous year[3] - The company's net profit attributable to shareholders was RMB -106,691.89 million, with a basic earnings per share of RMB -2.67[3] - The company reported a weighted average return on equity of -51.67%, a decrease of 17.13 percentage points from -34.54% in the previous year[3] Assets and Equity - Total assets decreased by 4.45% to RMB 425,701.55 million from RMB 445,504.84 million[4] - Shareholders' equity attributable to the parent company decreased by 40.17% to RMB 154,593.85 million, with net asset value per share dropping by 40.19% to RMB 3.87[4] Revenue Drivers - The increase in revenue was primarily driven by significant sales growth of the drug Mai Li Shu® and the approval of Mai Wei Jian® in March 2024[5] Research and Development - The company maintained a high level of R&D investment as multiple innovative drugs are in critical trial stages[6] Operating Costs - Operating costs and sales expenses increased due to further market expansion and commercialization efforts[5] Financial Data Caution - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[7] - Investors are advised to be cautious due to potential investment risks associated with the preliminary financial data[7]

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688062 证券简称：迈威生物 公告编号：2025-006 迈威（上海）生物科技股份有限公司 第二届监事会第十五次会议决议公告 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见与本公告同日刊登于上海证券交易所网站（www.sse.com.cn） 的《迈威（上海）生物科技股份有限公司关于继续使用部分暂时闲置募集资金 进行现金管理的公告》。 特此公告。 迈威（上海）生物科技股份有限公司 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第十五次会议通知于 2025 年 1 月 17 日以书面方式送达全体监事，于 2025 年 1 月 22 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议应到 监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》等法 律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司章 程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一 ...

海通证券股份有限公司 1 二、本次继续使用部分暂时闲置募集资金进行现金管理的基本情况 （一）投资目的 为提高募集资金使用效率，在不影响募投项目开展、募集资金使用计划和保 证募集资金安全的前提下，公司及全资子公司将合理利用部分暂时闲置募集资金 进行现金管理，提高募集资金使用效益、增加股东回报。 关于迈威（上海）生物科技股份有限公司 继续使用部分暂时闲置募集资金进行现金管理的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为迈威 （上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）首次公开 发行股票并上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海 证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第11 号——持续督导》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等有关规定，对公司继续使用部分暂时闲置募集资金进行现金管理的事项 进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 12 月 7 日出具的《关于同意迈威 （ ...

Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -970 million and -1,160 million CNY, continuing the trend of losses compared to the previous year [2]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -1,000 million and -1,190 million CNY [2]. - The total profit for the previous year was -1,055.29 million CNY, with a net profit attributable to shareholders of the parent company at -1,053.43 million CNY [5]. - The company anticipates continued negative net profit attributable to shareholders of the parent company for the 2024 fiscal year [6]. Sales and Market Expansion - The company reported a significant increase in sales revenue due to market expansion, particularly from the drug Mai Li Shu®, which saw a substantial rise in sales compared to the previous year [6]. - The drug Mai Wei Jian® was approved for market launch in March 2024, contributing to increased sales revenue [6]. Operating Costs and R&D - Operating costs and sales expenses have increased in line with the expansion of commercialization efforts [6]. - The company maintains a high level of research and development investment, with multiple innovative drugs in critical trial stages [6]. Forecast Accuracy and Data Status - There are no significant uncertainties affecting the accuracy of this earnings forecast [7]. - The data provided is preliminary and subject to change, with final audited financial data to be disclosed in the 2024 annual report [8].

迈威（上海）生物科技股份有限公司 2024 年第四次临时股东大会会议资料 2024 年 12 月 | 目录 | | --- | | 2024 年第四次临时股东大会会议须知 | | 3 | | --- | --- | --- | | 年第四次临时股东大会会议议程 2024 | | 5 | | 2024 年第四次临时股东大会会议议案 | | 8 | | 议案一 关于公司于境外公开发行股票（H | 股）并在香港联合交易所有限公司 | | | 主板上市的议案 | | 8 | | 议案二 关于公司于境外公开发行股票（H | 股）并在香港联合交易所有限公司主 | | | 板上市方案的议案 | | 9 | | 议案三 关于公司转为境外募集股份有限公司的议案 | | 13 | | 议案四 关于公司境外公开发行 股募集资金使用计划的议案 H | | 14 | | 议案五 关于公司境外公开发行 H 股并上市决议有效期的议案 | | 15 | | 议案六 关于授权董事会及其获授权人士全权处理与本次境外首次公开发行 | | H | | 股并上市有关事项的议案 | | 16 | | 议案七 关于境外公开发行 H 股前滚存利润分配方式的 ...

Group 1 - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to meet funding needs and enhance internationalization [1] - The company is in discussions with intermediaries regarding the H-share issuance, with significant uncertainties regarding approval and implementation [1] - The company aims to leverage the national strategy for the western development to expand both domestic and international markets through a partnership with the Chongqing High-tech Zone Management Committee [1][4] Group 2 - The total planned investment for the bone health innovation drug project is 2 billion yuan, with the company investing no less than 1.6 billion yuan [2] - The project will be operated by the company's wholly-owned subsidiary, and the registered capital of this subsidiary will be increased from 20 million yuan to 1.008 billion yuan [2][3] - The investment will include contributions in the form of intangible assets, specifically the technology achievements of an already listed biological drug [2][3] Group 3 - The project will allow the subsidiary to become the marketing authorization holder for the drug, gaining rights for research, production, and commercialization [3] - The project aims to establish a national marketing center and conduct clinical research for expanding indications of the drug [3][4] - The local government will support the company's drug promotion and services, targeting over 1 million elderly individuals annually [4][5]

海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 预计2025年度日常关联交易的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为迈威 （上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）首次公开 发行股票并上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指 引第11号——持续督导》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等有关规定，对公司预计2025年度日常关联交易事项进行了核查， 具体情况如下： 一、日常关联交易概况 （一）日常关联交易履行的审议程序 1、公司董事会审计委员会审议程序 公司于2024年12月10日召开第二届董事会审计委员会第十二次会议，通过了 《关于预计2025年度日常关联交易的议案》，并同意将该议案提交至公司董事会 审议。 2、公司董事会审议程序 公司于2024年12月15日召开第二届董事会第十五次会议，审议通过了《关于 预计2025年度日常关联交易的议案》，关联董事唐春山回避了相关事项的表决， 相关议案获出席会议的非关联董事一致表决通过。本 ...